Lonza eyes revenue growth this year after 2023 challenges, plans to close second biologics site in a month
After a year of navigating “shifting market dynamics,” Lonza reported on Friday it had a 7.9% sales revenue increase for 2023 compared to the previous year. But it is closing another biologics facility, this time in China, despite this division being one of the company’s main revenue drivers.
The manufacturer previously evaded detailed 2024 forecasts during its Capital Markets Day in October, but now it reaffirms its guidance for the year, predicting a growth margin in the “high twenties.” Also, its four-year projection is forecast at 11% to 13% sales growth, the company said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.